Pharmacogenomic study to predict warfarin stable dose in Japanese chidren.
Phase 3
- Conditions
- congenital heart disease, Kawasaki disease, myocardiac disease, thromboembolism
- Registration Number
- JPRN-UMIN000019397
- Lead Sponsor
- ational Center for Child Health and Development
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 480
Inclusion Criteria
Not provided
Exclusion Criteria
Patients whose warfarin dose has been changed within 28 days of the date of DNA sample collection Pregnant women and lactating women Patients who did not give written informed consent Patients who regularly (at least once/week) consume vitamin K-rich foods and supplements such as natto, chlorella, green juice, and St. John's wort (Hypericum perforatum) Patients who are judged by the attending physician to be inappropriate as subjects for this study
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method warfarin stable dose
- Secondary Outcome Measures
Name Time Method